InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: Protector post# 223715

Wednesday, 06/17/2015 6:49:46 AM

Wednesday, June 17, 2015 6:49:46 AM

Post# of 346475
good post CP and I'm looking forward to the July conference call.

Peregrine continues to move forward. Lets just hope there is a new analyst on board that can inject some interesting questions to try and extract a bit more information from them.

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News